Ritter Pharmaceuticals Inc (NASDAQ:RTTR) hit a new 52-week low during trading on Thursday . The stock traded as low as $0.80 and last traded at $0.82, with a volume of 9527 shares. The stock had previously closed at $1.07.
Several equities research analysts recently commented on the stock. ValuEngine lowered shares of Ritter Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, October 29th. Zacks Investment Research raised shares of Ritter Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, August 1st. Finally, HC Wainwright reissued a “buy” rating and issued a $15.00 price target on shares of Ritter Pharmaceuticals in a report on Wednesday, August 15th.
The firm has a market capitalization of $5.37 million, a PE ratio of -0.18 and a beta of 1.21.
Ritter Pharmaceuticals (NASDAQ:RTTR) last released its earnings results on Tuesday, August 14th. The biotechnology company reported ($0.71) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.56) by ($0.15). Analysts predict that Ritter Pharmaceuticals Inc will post -2.97 EPS for the current year.
In other Ritter Pharmaceuticals news, Director Matthew W. Foehr bought 19,751 shares of the company’s stock in a transaction dated Friday, August 17th. The stock was acquired at an average price of $2.04 per share, with a total value of $40,292.04. Following the completion of the acquisition, the director now directly owns 54,751 shares of the company’s stock, valued at $111,692.04. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 21.60% of the stock is owned by corporate insiders.
COPYRIGHT VIOLATION NOTICE: “Ritter Pharmaceuticals (RTTR) Reaches New 1-Year Low at $0.80” was originally reported by Stock Observer and is owned by of Stock Observer. If you are viewing this piece on another site, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The correct version of this piece can be viewed at https://www.thestockobserver.com/2018/11/10/ritter-pharmaceuticals-rttr-reaches-new-1-year-low-at-0-80.html.
Ritter Pharmaceuticals Company Profile (NASDAQ:RTTR)
Ritter Pharmaceuticals, Inc develops and sells novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b clinical trial for the reduction of symptoms associated with lactose intolerance.
Further Reading: How Do Tariffs Affect Trade Balances?
Receive News & Ratings for Ritter Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.